This study aims to assess whether, and the degree to which, ofatumumab modulates or reduces rates of retinal atrophy in people with relapsing-remitting MS (RMS), according to baseline serum neurofilament light chain (sNfL) levels.
Seventy-five people with RMS who due to commence or already receiving ofatumumab therapy within 60 days of baseline will be recruited. All recruited participants will be tracked prospectively over a two-year period. Participants will complete an optical coherence tomography (OCT) scan, visual acuity (VA) assessments, EDSS, and sNfL blood level at baseline and every 6 months. Participants will be tracked prospectively for 2 years. OCT scans, sNfL levels, disability score determinations, 100% high-contrast, 2.5% and 1.25% low-contrast letter acuities will be performed every 6 months. Results from an existing cohort of approximately 75 healthy controls (HC) from a separate study undergoing annual OCT and visual function assessments will be used for comparison purposes.
Have RMS as confirmed by the treating neurologist based on the 2017 revised McDonald criteria
AND Either
be due to commence ofatumumab within 60 days of baseline OCT/VA/phlebotomy or be existing patients attending the center and already receiving ofatumumab, be eligible for inclusion, and already undergoing all of the proposed study procedures. Willing to sign informed consent Willing to undergo phlebotomy
Exclusion Criteria:
Uncontrolled Diabetes Uncontrolled Hypertension Glaucoma Refractive errors of +/- 6 diopters Other neurologic or ophthalmologic disorders
